YuanShi Technology Raises Nearly RMB 300M for AI Virtual Cells
Shanghai AI drug-discovery startup YuanShi Technology announced nearly RMB 300 million in Pre-A funding led by Legend Capital, with ChinaAMC, a JD.com affiliate fund and CMC Capital among the investors. The company plans to use the proceeds to collect cell-intervention data, build an automated experimental platform, iterate its general cell foundation model and expand its research team. YuanShi Technology says its virtual-cell models predict cellular responses across disease states, experimental conditions and interventions, then use experimental results to train and update the models.
The financing provides substantial capital for an AI virtual-cell company building a data-and-experiment feedback loop, while its claimed financing record remains unverified.

智东西 作者 | 孙小雯 编辑 | 程茜
智东西11月19日消息,今日,上海AI制药创企元示科技宣布,完成近3亿元人民币Pre-A轮融资,并宣称刷新国内AI虚拟细胞(AIVC)领域的单笔融资纪录。
这是元示科技近一个月内官宣的第三轮融资,本轮融资由君联资本领投,华夏瓴投、京东关联基金、CMC资本等跟投,光源资本担任独家财务顾问。今年10月,元示科技宣布已连续完成近亿元人民币天使轮及天使+轮融资。
该公司计划将新资金主要用于积累细胞干预与响应数据、建设自动化实验平台、迭代通用细胞大模型及扩充研发团队。
元示科技于今年4月成立,主要研发AI虚拟细胞模型,旨在预测细胞在不同疾病状态、实验条件和干预方式下的响应。此外,该公司同步建设实验数据生产体系,通过实验检验模型预测,并将结果用于后续训练与更新。该公司称,这一迭代过程为递归自我改进(RSI)在生物基础模型中的应用。
#YuanShi Technology#Legend Capital#ChinaAMC#JD.com#CMC Capital#Lighthouse Capital#MGI Tech#Yongsheng Intelligence#AI virtual cell models